Atovaquone for Platinum-Resistant Ovarian Cancer
Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Recruiting
Phase 2
Interventional Study
Ovarian High Grade Serous Adenocarcinoma
Platinum-Resistant Ovarian Carcinoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Female
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 28 (estimated)
- Sponsor
- Emory University · Other
Who this trial is looking for
This trial is looking for patients with a specific type of ovarian cancer that has not responded to chemotherapy. Participants will take a medication called atovaquone to see if it helps improve their condition.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with platinum-resistant high-grade serous ovarian cancer.
- My cancer progressed within six months after my last platinum-based chemotherapy.
- I have an ECOG performance status of 0 or 1.
- I can be a non-English speaking patient.
- I have no limitations on the number of prior treatments I have received.
- I have been referred from community practice.
You may not be able to join if
- I am under 18 years old.
- I am pregnant or breastfeeding.
- I am currently incarcerated.
- I cannot provide consent or lack decision-making capacity.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. Giving atovaquone may be effective in tr…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients with platinum-resistant, high-grade serous ovarian cancer, defined as disease progression within six months of completion of their last platinum-based chemotherapy
* Patients must maintain Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* There …
Contacts